Significant Ownership of Peter Evan Harwin
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Peter Evan Harwin focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager location
- West Conshohocken, PA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
1 identity field
Follow Filing Activity
Follow Peter Evan Harwin with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Peter Evan Harwin
Significant Ownership of Peter Evan Harwin
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ORKA | ORUKA THERAPEUTICS, INC. | Common Stock, $0.001 par value per share | 20% | $997,807,627 | +$62,159,599 | 14,572,917 | +6.6% | Harwin Peter Evan | 01 Jul 2026 |
| CBIO | Crescent Biopharma, Inc. | Ordinary Shares, $0.001 par value | 17% | $118,843,344 | +$17,260,668 | 6,602,408 | +17% | Peter Harwin | 16 Jul 2026 |
| SYRE | SPYRE THERAPEUTICS, INC. | Common Stock, $0.0001 par value | 10% | $906,856,108 | +$46,185,203 | 10,185,961 | +5.4% | Harwin Peter Evan | 07 Oct 2026 |
Schedules 13D/G Reported by Peter Evan Harwin:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.